Major Investor Increases Stake in Processa Pharmaceuticals with $200K Purchase
PCSA is trading near its 52-week low of $2.03 (2.8% above the low).
Summary
A 10% owner, The Chiliz Group Ltd, invested an additional $200,000 in Processa Pharmaceuticals, increasing its beneficial ownership to 13.0% of outstanding shares.
Key Events · Ownership and Investor Activity · PCSA
-
Significant Share Purchase
The Chiliz Group Ltd (formerly HX Entertainment Ltd) acquired 86,956 shares of common stock for $200,000 on February 13, 2026.
-
Increased Ownership Stake
This purchase increases The Chiliz Group's beneficial ownership to 305,644 shares, representing 13.0% of Processa Pharmaceuticals' outstanding common stock.
-
Investment at Premium to Current Market
The shares were acquired at $2.30 per share, which was above the current market price of $2.0867 and near the 52-week low at the time of the transaction, indicating investor conviction.
Analysis · PCSA · Life Sciences
The Chiliz Group Ltd, a significant 10% owner, increased its stake in Processa Pharmaceuticals by purchasing an additional 86,956 shares for $200,000. This transaction, executed at $2.30 per share on February 13, 2026, demonstrates continued confidence in the company, especially as the purchase price was above the stock's current trading level and near its 52-week low at the time of the transaction. This follows a previous substantial investment in August 2025 and reinforces the investor's strategic interest, despite the recent news on February 19, 2026, regarding the expiration of a binding term sheet for PCS12852.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.6% of the 1742 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSA was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $2.03 to $19.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.